FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasimigton,	D.C.	20040

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Ring Christine					- <u>N</u> ı	2. Issuer Name and Ticker or Trading Symbol Nurix Therapeutics, Inc. [NRIX]											ationship of Reporting all applicable) Director Officer (give title below)		son(s) to Iss 10% Ov Other (s below)	wner
(Last) (First) (Middle) C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205							of Earli 2021	est Trar	nsact	tion (Mor	nth/[Day/Year)		General Counsel						
(Street) SAN FRANCI			94158		4. I										Line	e) X Form t Form t	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(5)		(Zip)																	
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/D		action	Execution Date,		<u>, </u>	3. 4. Secu Transaction Dispos Code (Instr. 5)		4. Securi	of, or Benefici rities Acquired (A) o ed Of (D) (Instr. 3, 4 a			5. Amou Securiti Benefic	int of es ally Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
										Code	/	Amount	Amount (A) or (D)		Price	Transac (Instr. 3	tion(s)			(11150.4)
Common Stock 11/1				11/10	0/2021	2021			M ⁽¹⁾		1,200 A \$		\$1.80	5 2,	2,486		D			
Common Stock 11/10			0/2021	2021				S ⁽¹⁾		1,200	1,200 D \$		\$32.3	8 1,	1,286		D			
		7	able II -									sed of onverti				Owned				*
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,		Transaction Code (Instr.		n of		5. Date Exercisabl Expiration Date Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	ly [10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	te ercisable		kpiration ate	Title	OI N Of	umber					
Employee Stock Option (right to	\$1.86	11/10/2021			M ⁽¹⁾			1,200		(2)	09	9/30/2029	Commo Stock		1,200	\$0.00	102,46	6	D	

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- 2. The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Remarks:

/s/ Christine Ring

11/12/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.